Eugia US LLC received FDA approval for its ANDA for tranexamic acid intravenous injection (2016), a generic version of the marketed hemostatic agent. This clearance expands generic competition in the IV anti-fibrolytic space, a segment known for high utilization in surgical and trauma settings.